FDA warning letter · Biologics

Amnio Technology, LLC

Issued · Posted by FDA

Selected passages from the FDA letter

Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.

Passage 1

Failure to follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)].** For example, the report for consumer complaint CC-000159 related to PalinGen® Flow® indicated that the incident involved a communicable disease and required medical/surgical intervention; however, you did not report this event to FDA within 15 days, as required by your written complaint procedure.

Citations in the original letter

As cited in this historical letter, not a statement of current regulatory requirements.

  • 21 CFR 1271.10(a)
  • 21 CFR 1271.3(d)
  • 21 CFR 1271.15
  • 21 CFR 1271.10(a)(2)
  • 21 CFR 1271
  • 21 CFR 1271.3(c)
  • 21 CFR 1271.10(a)(1)
  • 21 CFR 1271.10(a)(3)
  • 21 CFR 210
  • 21 CFR 211.100(a)
  • 21 CFR 211.166(a)
  • 21 CFR 211.198(a)
  • 21 CFR 312